Open Access Green as soon as Postprint is submitted to ZB.
		
    Predicting type 1 diabetes.
        
        Curr. Diab. Rep. 5, 98-103 (2005)
    
    
    
	    Predicting type 1 diabetes mellitus (T1DM) is a prerequisite for disease prevention. Prediction is currently performed on three levels, which include the genetic susceptibility for disease, the identification of preclinical T1DM by way of circulating islet autoantibodies, and the use of metabolic tests to stage preclinical disease into late or early prediabetes. Combinations of genetic markers such as HLA genotype, INS genotype, and if and how much family history of T1DM is present can stratify disease risk more than 1000-fold, and can be used for selection of first-degree relatives of patients with T1DM for primary intervention trials. Measurement of autoantibodies in genetically at-risk subjects identifies future cases of T1DM. Further stratification of diabetes risk in autoantibody-positive subjects can be made on the basis of autoantibody characteristics that correspond to the magnitude of the autoantibody response.
	
	
      Impact Factor
		Scopus SNIP
		
		
		Altmetric
		
	    0.000
		0.000
		
		
		
	    Annotations
	    
		
		     
		    
		
	    
	
		
	
	    Special Publikation
	    
		
		     
		
	    
	
	
	
	    Hide on homepage
	    
		
		     
		
	    
	
	
        Publication type
        Article: Journal article
    
 
    
        Document type
        Scientific Article
    
 
     
    
     
     
    
    
        Language
        english
    
 
    
        Publication Year
        2005
    
 
     
    
        HGF-reported in Year
        0
    
 
    
    
        ISSN (print) / ISBN
        1534-4827
    
 
    
        e-ISSN
        1539-0829
    
 
    
     
     
	     
	 
	 
    
        Journal
        Current Diabetes Reports
    
 
	
    
        Quellenangaben
        
	    Volume: 5,  
	    Issue: 2,  
	    Pages: 98-103 
	    
	    
	
    
 
    
         
        
            Publisher
            Springer
        
 
        
            Publishing Place
            Heidelberg [u.a.]
        
 
	
         
         
         
         
         
	
         
         
         
    
         
         
         
         
         
         
         
    
        Reviewing status
        Peer reviewed
    
 
    
        Institute(s)
        Institute of Diabetes Research (IDF)
Institute of Diabetes and Obesity (IDO)
Institute of Pancreatic Islet Research (IPI)
 
    Institute of Diabetes and Obesity (IDO)
Institute of Pancreatic Islet Research (IPI)
        POF-Topic(s)
        30201 - Metabolic Health
30502 - Diabetes: Pathophysiology, Prevention and Therapy
    
 
    30502 - Diabetes: Pathophysiology, Prevention and Therapy
        Research field(s)
        Helmholtz Diabetes Center
    
 
    
        PSP Element(s)
        G-502100-001
G-502290-001
 
     
     	
    G-502290-001
        PubMed ID
        15794911
    
    
        Erfassungsdatum
        2005-04-00